Related Experiment Videos
Marie Senant1, Delphine Giusti1, Laurence Weiss2
1Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Service d'immunologie biologique, hôpital européen Georges-Pompidou, Assistance publique-hôpitaux de Paris.
Bulletin Du Cancer
|January 7, 2017
Summary
Immune checkpoint inhibitors (ICIs) like CTLA-4 and PD-1 block self-tolerance, potentially causing autoimmune side effects (irAEs). Management strategies are crucial for patients receiving these cancer immunotherapies.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Immune checkpoint molecules (CTLA-4, PD-1) regulate self-tolerance by inhibiting lymphocyte activation.
- Tumor microenvironments often exploit these checkpoints to suppress anti-tumor immunity.
- Immune checkpoint inhibitors (ICIs) are therapies designed to block these inhibitory signals, enhancing anti-tumor responses.
Purpose of the Study:
- To review the role of immune checkpoint molecules in self-tolerance and autoimmune diseases.
- To summarize the immune-related adverse events (irAEs) associated with ICI therapy.
- To provide guidelines for monitoring and managing irAEs in patients treated with ICIs.
Main Methods:
- Literature review of scientific data on immune checkpoints, tolerance, and autoimmunity.
- Analysis of reported irAEs in patients undergoing ICI treatment.
- Synthesis of current guidelines for irAE management.
Main Results:
- Immune checkpoint blockade can disrupt peripheral tolerance, leading to autoimmune manifestations.
- A significant proportion of patients treated with ICIs develop irAEs affecting various organs.
- Management strategies for irAEs are essential for patient safety and treatment continuation.
Conclusions:
- Immune checkpoint inhibitors, while effective in cancer therapy, carry a risk of inducing autoimmunity.
- Understanding the mechanisms of irAEs is key to developing effective management protocols.
- Proactive monitoring and timely intervention are critical for managing irAEs in patients receiving ICIs.